Ross Darwin is listed as a director on 3 SEC Form D filings by 2 issuers between Mar 2021 and Mar 2022: Preply, Inc. (Brookline, MA — other technology — 2021–2022; $101.5M reported sold to 25 investors) and Aviceda Therapeutics, Inc. (Cambridge, MA — biotechnology — 2022; $75M reported sold to 18 investors).
What this means 2 separate companies raised money with this person listed as director. Across those companies the filings report $176.5M sold in total.
Listed alongside Dmytro Voloshyn (3 shared filings), Kyrylo Bigay (3 shared filings), Mariusz Gralewski (3 shared filings) and Robert Kniaz (3 shared filings).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Ross. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 3 public filings for Ross Darwin and found 4 differences: No amendment in the last 12 months on an offering that may still be open; Same name, different state: "Ross Darwin" (O5) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.